ARPA-H awarded up to $87 million for its BioStabilization Systems (BoSS) program, funding three teams to address cold-chain bottlenecks for cell-based biologics. The initiative aims to enable long-term shelf stability and on-demand reactivation, with support structured for Phase I work over four years. One team, the Reversible Ambient Temperature (RAB) group led by Draper (administrative lead) and Likarda (technical lead), is set to receive up to $7.3 million initially. Participants include CaseBioscience, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the University of Colorado. The funding focuses on stabilizing cells for storage, creating scalable bioprocessing workflows, and developing processing systems to support room-temperature shipping without refrigeration. Delivering stable, reactivatable products could materially change logistics economics and access for CAR-T and other cell therapies.